News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.
"We are very confident with both the auto-injectors and the vials that we will be able to supply the needs in the U.S. marketplace," he said, adding that a big chunk of patients do not progress to ...
By Maggie Fick and Louise Rasmussen Sept 20 (Reuters) - Swiss medical technology company Ypsomed YPSN.S announced on Wednesday a long-term supply deal with Novo Nordisk NOVOb.CO for autoinjectors ...
Meanwhile, the company signed on to a long-term manufacturing deal with Novo Nordisk to provide autoinjectors for the drugmaker’s blockbuster GLP-1 drugs Wegovy and Ozempic.
Lilly launches lower-price weight loss drug without injector pen By Deidre McPhillips, CNN | Posted - Aug. 27, 2024 at 2:36 p.m.
It targets two hormone receptors, GIP and GLP-1. Semgalutide, known as Ozempic for diabetes and Wegovy for weight loss, is also part of this broad class of drugs.
It targets two hormone receptors, GIP and GLP-1. Semgalutide, known as Ozempic for diabetes and Wegovy for weight loss, is also part of this broad class of drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results